BR112016022787A2 - método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica - Google Patents

método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica

Info

Publication number
BR112016022787A2
BR112016022787A2 BR112016022787-5A BR112016022787A BR112016022787A2 BR 112016022787 A2 BR112016022787 A2 BR 112016022787A2 BR 112016022787 A BR112016022787 A BR 112016022787A BR 112016022787 A2 BR112016022787 A2 BR 112016022787A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
inducing
immune response
human subject
administration
Prior art date
Application number
BR112016022787-5A
Other languages
English (en)
Inventor
Ripley Ballou William Jr
Michel Didierlaurent Arnaud
Gerrit Van Der Most Robbert
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of BR112016022787A2 publication Critical patent/BR112016022787A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

são fornecidos métodos e usos para induzir uma resposta imune compreendendo pelo menos duas administrações de uma composição imunogênica, em que na segunda administração é dada uma dose menor que na primeira administração, e em que a segunda administração pode estar não adjuvantada.
BR112016022787-5A 2014-04-02 2015-04-02 método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica BR112016022787A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405921.6 2014-04-02
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057424 WO2015150568A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
BR112016022787A2 true BR112016022787A2 (pt) 2018-03-27

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016022463A BR112016022463A2 (pt) 2014-04-02 2015-04-02 método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica
BR112016022787-5A BR112016022787A2 (pt) 2014-04-02 2015-04-02 método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112016022463A BR112016022463A2 (pt) 2014-04-02 2015-04-02 método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica

Country Status (18)

Country Link
US (3) US10688168B2 (pt)
EP (2) EP3125929B8 (pt)
JP (2) JP6655549B2 (pt)
KR (2) KR20160132115A (pt)
CN (2) CN106456738B (pt)
AR (1) AR099960A1 (pt)
AU (1) AU2015239025B2 (pt)
BE (1) BE1022355B1 (pt)
BR (2) BR112016022463A2 (pt)
CA (2) CA2943007C (pt)
EA (1) EA037405B1 (pt)
ES (2) ES2961840T3 (pt)
GB (1) GB201405921D0 (pt)
IL (1) IL247493B (pt)
MX (3) MX2016012932A (pt)
SG (1) SG11201607086QA (pt)
WO (2) WO2015150567A1 (pt)
ZA (1) ZA201605955B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
AU2005293572B2 (en) 2004-10-14 2011-08-04 Crucell Holland B.V. Malaria prime/boost vaccines
KR20150036658A (ko) * 2005-04-29 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008140478A2 (en) * 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
EA021391B1 (ru) * 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
KR20110060891A (ko) * 2008-07-25 2011-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 신규한 조성물 및 방법
CN106866801A (zh) * 2008-07-25 2017-06-20 葛兰素史密丝克莱恩生物有限公司 结核病rv2386c蛋白、组合物及其用途
CA2731499C (en) * 2008-07-25 2017-01-10 Glaxosmithkline Biologicals S.A. Composition and use thereof for treating or preventing latent tuberculosis
UA110103C2 (uk) * 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген
KR101951894B1 (ko) * 2010-12-14 2019-02-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 미코박테리움 항원성 조성물
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
BR112016023778A2 (pt) * 2014-04-24 2017-10-17 Statens Seruminstitut proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
EA201691638A1 (ru) 2017-04-28
EP3125929C0 (en) 2023-11-01
IL247493B (en) 2022-08-01
EP3125929A1 (en) 2017-02-08
CA2943007A1 (en) 2015-10-08
US20200306353A1 (en) 2020-10-01
WO2015150567A1 (en) 2015-10-08
AU2015239025A1 (en) 2016-09-22
CN106456738A (zh) 2017-02-22
AU2015239025B2 (en) 2018-01-25
BE1022355B1 (fr) 2016-03-26
ZA201605955B (en) 2019-04-24
EP3125929B1 (en) 2023-11-01
BE1022355A1 (fr) 2016-02-16
MX2022013912A (es) 2022-12-13
US11951161B2 (en) 2024-04-09
CA2943007C (en) 2024-01-09
BR112016022463A2 (pt) 2017-10-10
JP6645982B2 (ja) 2020-02-14
WO2015150568A1 (en) 2015-10-08
US20170136110A1 (en) 2017-05-18
SG11201607086QA (en) 2016-09-29
KR20230075525A (ko) 2023-05-31
IL247493A0 (en) 2016-11-30
MX2016012932A (es) 2016-12-07
EP3125930B1 (en) 2020-12-02
JP2017511324A (ja) 2017-04-20
JP6655549B2 (ja) 2020-02-26
JP2017511327A (ja) 2017-04-20
EP3125930A1 (en) 2017-02-08
CN106456738B (zh) 2021-06-29
EP3125929B8 (en) 2023-12-27
GB201405921D0 (en) 2014-05-14
EA037405B1 (ru) 2021-03-25
US10688168B2 (en) 2020-06-23
KR20160132115A (ko) 2016-11-16
US10624961B2 (en) 2020-04-21
ES2961840T3 (es) 2024-03-14
US20170112914A1 (en) 2017-04-27
CN106456739A (zh) 2017-02-22
AR099960A1 (es) 2016-08-31
CA2943711A1 (en) 2015-10-08
ES2853773T3 (es) 2021-09-17
MX2016012982A (es) 2016-12-07

Similar Documents

Publication Publication Date Title
BR112016022787A2 (pt) método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
DK3244917T3 (da) Immunogene sammensætninger til anvendelse i pneumokokvacciner
DK3570879T3 (da) Immunogene sammensætninger til anvendelse i pneumokokvacciner
PE20170278A1 (es) Composiciones de bioceramica y usos biomoduladores de las mismas
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling
AR100608A1 (es) Complejos de citomegalovirus y usos de los mismos
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
DK3558391T3 (da) Immunkonjugater med adam9 som mål og fremgangsmåder til anvendelse deraf
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
BR112017018948A2 (pt) método
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
DK3355933T3 (da) Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser
BR112018008697A2 (pt) método e kit para vacinação contra um auto-antígeno, uso de um kit, e, vacina para uso em vacinação.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.